Literature DB >> 25846986

Animal models of Epstein Barr virus infection.

Cornelia Gujer1, Bithi Chatterjee1, Vanessa Landtwing1, Ana Raykova1, Donal McHugh1, Christian Münz2.   

Abstract

Epstein Barr virus (EBV) was the first human tumor virus to be described. Despite its discovery now more than fifty years ago, immune control of this virus is still not very well understood and no vaccine is available. This knowledge gap is due in part to the lack of a preclinical small animal model which can faithfully recapitulate EBV infection and immune control, and would allow testing of EBV specific vaccine candidates. With the advent of mice with reconstituted human immune system compartments (HIS mice) during the past decade this is changing. We will discuss which aspects of EBV infection and its immune control can already be modeled in HIS mice, and which shortcomings still need to be overcome in order to recapitulate the immunobiology of oncogenic EBV infection.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25846986     DOI: 10.1016/j.coviro.2015.03.014

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN: 1879-6257            Impact factor:   7.090


  13 in total

1.  Dynamics of Sendai Virus Spread, Clearance, and Immunotherapeutic Efficacy after Hematopoietic Cell Transplant Imaged Noninvasively in Mice.

Authors:  Heba H Mostafa; Peter Vogel; Ashok Srinivasan; Charles J Russell
Journal:  J Virol       Date:  2018-01-02       Impact factor: 5.103

Review 2.  Manipulation of the host cell membrane by human γ-herpesviruses EBV and KSHV for pathogenesis.

Authors:  Fang Wei; Qing Zhu; Ling Ding; Qing Liang; Qiliang Cai
Journal:  Virol Sin       Date:  2016-09-12       Impact factor: 4.327

Review 3.  Humanized Mouse Models of Clinical Disease.

Authors:  Nicole C Walsh; Laurie L Kenney; Sonal Jangalwe; Ken-Edwin Aryee; Dale L Greiner; Michael A Brehm; Leonard D Shultz
Journal:  Annu Rev Pathol       Date:  2016-12-05       Impact factor: 23.472

4.  The Incubation Period of Primary Epstein-Barr Virus Infection: Viral Dynamics and Immunologic Events.

Authors:  Samantha K Dunmire; Jennifer M Grimm; David O Schmeling; Henry H Balfour; Kristin A Hogquist
Journal:  PLoS Pathog       Date:  2015-12-01       Impact factor: 6.823

5.  EBV persistence without its EBNA3A and 3C oncogenes in vivo.

Authors:  Anita Murer; Donal McHugh; Nicole Caduff; Jens Kalchschmidt; Mario Barros; Andrea Zbinden; Riccarda Capaul; Gerald Niedobitek; Martin Allday; Obinna Chijioke; Christian Münz
Journal:  PLoS Pathog       Date:  2018-04-30       Impact factor: 6.823

Review 6.  Dangerous Liaisons: Gammaherpesvirus Subversion of the Immunoglobulin Repertoire.

Authors:  Monika A Zelazowska; Kevin McBride; Laurie T Krug
Journal:  Viruses       Date:  2020-07-23       Impact factor: 5.048

7.  Antibody Generation and Immunogenicity Analysis of EBV gp42 N-Terminal Region.

Authors:  Junping Hong; Dongmei Wei; Qian Wu; Ling Zhong; Kaiyun Chen; Yang Huang; Wanlin Zhang; Junyu Chen; Ningshao Xia; Xiao Zhang; Yixin Chen
Journal:  Viruses       Date:  2021-11-28       Impact factor: 5.048

Review 8.  The Status and Prospects of Epstein-Barr Virus Prophylactic Vaccine Development.

Authors:  Cong Sun; Xin-Chun Chen; Yin-Feng Kang; Mu-Sheng Zeng
Journal:  Front Immunol       Date:  2021-06-08       Impact factor: 7.561

9.  Computer-Aided Design of an Epitope-Based Vaccine against Epstein-Barr Virus.

Authors:  Julio Alonso-Padilla; Esther M Lafuente; Pedro A Reche
Journal:  J Immunol Res       Date:  2017-09-28       Impact factor: 4.818

10.  Epstein-Barr Viruses (EBVs) Deficient in EBV-Encoded RNAs Have Higher Levels of Latent Membrane Protein 2 RNA Expression in Lymphoblastoid Cell Lines and Efficiently Establish Persistent Infections in Humanized Mice.

Authors:  Goran Gregorovic; Elizabeth A Boulden; Rachel Bosshard; Claudio Elgueta Karstegl; Rebecca Skalsky; Bryan R Cullen; Cornelia Gujer; Patrick Rämer; Christian Münz; Paul J Farrell
Journal:  J Virol       Date:  2015-09-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.